RhumbLine Advisers
ASND icon

RhumbLine Advisers’s Ascendis Pharma A/S ASND Stock Holding History

RhumbLine Advisers’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13M Buy
48,612
+46,887
+2,718% +$11M 0.01% 972
2026
Q1 		$395K Sell
1,725
-14
-0.8% -$3.14K ﹤0.01% 2751
2025
Q4 		$371K Buy
1,739
+604
+53% +$125K ﹤0.01% 2847
2025
Q3 		$226K Sell
1,135
-306
-21% -$57.1K ﹤0.01% 3164
2025
Q2 		$249K Buy
1,441
+55
+4% +$8.96K ﹤0.01% 3107
2025
Q1 		$216K Sell
1,386
-74
-5% -$10.6K ﹤0.01% 3069
2024
Q4 		$201K Sell
1,460
-108
-7% -$14.2K ﹤0.01% 3198
2024
Q3 		$234K Buy
1,568
+35
+2% +$4.73K ﹤0.01% 3157
2024
Q2 		$209K Buy
1,533
+143
+10% +$19.5K ﹤0.01% 3202
2024
Q1 		$210K Buy
1,390
+100
+8% +$14.3K ﹤0.01% 3151
2023
Q4 		$162K Buy
1,290
+22
+2% +$2.19K ﹤0.01% 3281
2023
Q3 		$119K Buy
1,268
+10
+0.8% +$936 ﹤0.01% 3401
2023
Q2 		$112K Buy
+1,258
New +$109K ﹤0.01% 3479

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

RhumbLine Advisers's ASND Position: Q2 2026 in Review

RhumbLine Advisers increased its Ascendis Pharma A/S (ASND) stake by 2,718% in Q2 2026, buying an estimated $11M and bringing the position to 48,612 shares worth $13M. The position accounts for 0.01% of the portfolio, ranked #972.

RhumbLine Advisers first reported a position in ASND in Q2 2023 and has held it in 13 quarters since. 313 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

  • RhumbLine Advisers held 48,612 shares of Ascendis Pharma A/S worth $13M as of Q2 2026.
  • RhumbLine Advisers bought 46,887 Ascendis Pharma A/S shares in Q2 2026, an estimated $11M.
  • Ascendis Pharma A/S made up 0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #972 holding.
  • RhumbLine Advisers first reported a position in Ascendis Pharma A/S in Q2 2023 and has held it in 13 quarters since.
  • 313 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.